Cargando…

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer

BACKGROUND AND AIMS: This study aimed to examine the safety of fixed‐dose nivolumab. METHODS: We retrospectively reviewed the medical records of 113 Japanese patients with gastric cancer who were previously treated with cytotoxic chemotherapy and initiated nivolumab. The endpoints were the incidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iikura, Yusuke, Aoyama, Takeshi, Hiraide, Makoto, Wakatsuki, Takeru, Nakayama, Izuma, Ogura, Mariko, Ooki, Akira, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Hama, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165198/ https://www.ncbi.nlm.nih.gov/pubmed/35662976 http://dx.doi.org/10.1002/hsr2.673

Ejemplares similares

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study
por: Shimozaki, Keitaro, et al.
Publicado: (2023)

Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy
por: Osumi, Hiroki, et al.
Publicado: (2020)

Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2021)

Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018
por: Nakayama, Izuma, et al.
Publicado: (2022)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2020)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
por: Fukuda, Koshiro, et al.
Publicado: (2023)

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake
por: Osumi, Hiroki, et al.
Publicado: (2018)

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
por: Nakayama, Izuma, et al.
Publicado: (2020)

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2019)

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
por: Takahari, Daisuke, et al.
Publicado: (2020)

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
por: Ushida, Yuta, et al.
Publicado: (2018)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2017)

Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting
por: Hatori, Masahiro, et al.
Publicado: (2021)

Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study
por: Takahari, Daisuke, et al.
Publicado: (2023)

The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review
por: Nakayama, Izuma, et al.
Publicado: (2023)

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
por: Shimozaki, K., et al.
Publicado: (2021)

Regorafenib-Induced Hand–Foot Skin Reaction Is More Severe on the Feet Than on the Hands
por: Nonomiya, Yuma, et al.
Publicado: (2019)

Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma
por: Nakayama, I., et al.
Publicado: (2023)

The dawn of precision medicine in diffuse-type gastric cancer
por: Ooki, Akira, et al.
Publicado: (2022)

Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era
por: Shimozaki, Keitaro, et al.
Publicado: (2023)

Immunotherapy in Colorectal Cancer: Current and Future Strategies
por: Ooki, Akira, et al.
Publicado: (2021)

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022)

Treatment Strategy for Esophageal Squamous Cell Carcinoma With Endoscopic Intramural Metastasis
por: Okamura, Akihiko, et al.
Publicado: (2022)

Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation
por: Udagawa, Shohei, et al.
Publicado: (2023)

Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults
por: Nakayama, Izuma, et al.
Publicado: (2019)

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
por: Aoyama, Takeshi, et al.
Publicado: (2023)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
por: Kawai, Sadayuki, et al.
Publicado: (2020)

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer
por: Kato, Ken, et al.
Publicado: (2020)

Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice
por: Nakayama, Izuma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vk9aj7lrpm7p06vqpg3ka3td4j